Published in J Thorac Oncol on July 01, 2010
Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol (2014) 1.25
Hypertrophic pulmonary osteoarthropathy with primary lung cancer. Oncol Lett (2014) 0.83
Hypertrophic pulmonary osteoarthropathy with positive antinuclear antibodies: case report. Case Rep Oncol (2012) 0.80
Lung carcinoma with hypertrophic osteoarthropathy in a teenager. Rare Tumors (2011) 0.79
Hypertrophic pulmonary osteoarthropathy on bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in a patient with lung adenocarcinoma. Indian J Nucl Med (2015) 0.75
Primary Idiopathic Osteoarthropathy: Could It Be Related to Alcoholism? Case Rep Rheumatol (2017) 0.75
18F-Fluoride bone positron emission tomography demonstrating changes related to finger clubbing and hypertrophic osteoarthropathy. Indian J Nucl Med (2014) 0.75
Multiple paraneoplastic syndromes revealing non-small cell lung carcinoma. Pan Afr Med J (2014) 0.75
A case of severe arthralgia with malignant mesothelioma-associated hypertrophic osteoarthropathy. Clin Case Rep (2016) 0.75
[Hypertrophic osteoarthropathy. Bamberger-Marie disease]. Z Rheumatol (2011) 0.75
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol (2003) 15.10
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med (2002) 7.59
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol (2008) 3.27
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med (2008) 3.00
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol (2002) 2.89
Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol (2004) 2.88
A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol (2011) 2.78
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol (2012) 2.44
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol (2013) 2.37
Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer (2009) 2.35
Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer (2008) 2.32
Pleomorphic carcinoma of the lung: clinicopathologic characteristics of 70 cases. Am J Surg Pathol (2008) 2.22
Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. J Clin Oncol (2002) 2.18
Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol (2006) 2.11
Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer. J Thorac Cardiovasc Surg (2005) 2.07
Pleural lavage cytology before and after lung resection in non-small cell lung cancer patients. Ann Thorac Surg (2006) 2.06
Prognostic impact of intratumoural microvascular invasion and microlymphatic permeation on node-negative non-small-cell lung cancer: which indicator is the stronger prognostic factor? Eur J Cardiothorac Surg (2012) 2.04
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics (2007) 2.01
Impact of extratumoral lymphatic permeation on postoperative survival of non-small-cell lung cancer patients. J Thorac Oncol (2014) 1.97
Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Lancet Oncol (2008) 1.87
Histopathologic prognostic factors in resected colorectal lung metastases. Ann Thorac Surg (2005) 1.71
Limited resection trial for pulmonary ground-glass opacity nodules: fifty-case experience. J Thorac Cardiovasc Surg (2005) 1.70
The clinical outcome of non-small cell lung cancer patients with adjacent lobe invasion: the optimal classification according to the status of the interlobar pleura at the invasion point. Eur J Cardiothorac Surg (2012) 1.69
Clinical heterogeneity in dysferlinopathy. Intern Med (2002) 1.68
Helical polymers: synthesis, structures, and functions. Chem Rev (2009) 1.66
Primary thymic mucosa-associated lymphoid tissue lymphoma: diagnostic tips. J Thorac Oncol (2010) 1.61
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol (2009) 1.61
Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer (2008) 1.59
Prognostic significance of a solid component in pulmonary adenocarcinoma. Ann Thorac Surg (2011) 1.59
Contribution of nicotine acetylcholine receptor polymorphisms to lung cancer risk in a smoking-independent manner in the Japanese. Carcinogenesis (2008) 1.57
Association between lung cancer incidence and family history of lung cancer: data from a large-scale population-based cohort study, the JPHC study. Chest (2006) 1.57
Predictive factors for suicidal ideation in patients with unresectable lung carcinoma. Cancer (2002) 1.55
Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res (2004) 1.54
A genome-wide association study identifies two new susceptibility loci for lung adenocarcinoma in the Japanese population. Nat Genet (2012) 1.51
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (2006) 1.49
Severe interstitial lung disease associated with amrubicin treatment. J Thorac Oncol (2010) 1.48
Influence of cigarette smoking on survival and tumor invasiveness in clinical stage IA lung adenocarcinoma. Ann Thorac Surg (2012) 1.44
Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol (2004) 1.42
Localized pure ground-glass opacity on high-resolution CT: histologic characteristics. J Comput Assist Tomogr (2002) 1.41
Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci (2013) 1.39
MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther (2013) 1.38
Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol (2003) 1.35
Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol (2008) 1.35
Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res (2008) 1.32
A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer. Curr Med Res Opin (2006) 1.30
Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer (2008) 1.27
Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression. Cancer Res (2011) 1.26
Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer (2008) 1.21
Long-term survival in two cases of resected gastric metastasis of pulmonary pleomorphic carcinoma. J Thorac Oncol (2008) 1.20
CD203c expression on human basophils is associated with asthma exacerbation. J Allergy Clin Immunol (2010) 1.20
Visceral pleura invasion impact on non-small cell lung cancer patient survival: its implications for the forthcoming TNM staging based on a large-scale nation-wide database. J Thorac Oncol (2009) 1.19
Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. J Thorac Oncol (2014) 1.19
Personalized medicine and proteomics: lessons from non-small cell lung cancer. J Proteome Res (2007) 1.18
Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. J Clin Oncol (2008) 1.16
Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci (2009) 1.15
Dynamic molecular changes associated with epithelial-mesenchymal transition and subsequent mesenchymal-epithelial transition in the early phase of metastatic tumor formation. Int J Cancer (2010) 1.15
Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. Carcinogenesis (2010) 1.15
Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thorac Oncol (2007) 1.15
Factors correlated with dyspnea in advanced lung cancer patients: organic causes and what else? J Pain Symptom Manage (2002) 1.14
Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer (2008) 1.14
Progression of focal pure ground-glass opacity detected by low-dose helical computed tomography screening for lung cancer. J Comput Assist Tomogr (2004) 1.13